Front Barnett Associates’s Moderna MRNA Stock Holding History

Front Barnett Associates’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-700	Closed	-$269K	–	120
2021 Q3	$269K	Buy	+700	New	+$258K	0.03%	108

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Front Barnett Associates's MRNA Position: Q4 2021 in Review

Front Barnett Associates sold out of Moderna (MRNA) in Q4 2021, closing a stake of 700 shares — an estimated $269K sold.

Front Barnett Associates first reported a position in MRNA in Q3 2021 and held it in 1 quarter. The position peaked at $269K in Q3 2021. 1,110 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

Front Barnett Associates reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
Front Barnett Associates sold 700 Moderna shares in Q4 2021, an estimated $269K.
Front Barnett Associates first reported a position in Moderna in Q3 2021 and held it in 1 quarter.
Front Barnett Associates's Moderna position peaked at $269K in Q3 2021.
1,110 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Front Barnett Associates's 13F filing for Q4 2021, filed 8 Feb 2022.